Variables | Insulin (N = 137) | OHA (N = 61) | P value |
---|---|---|---|
Baseline BCVA (approxETDRS letters) | 64.08 (12.99) | 64.07 (12.60) | 0.994 |
Baseline CMT (microns) | 380.33 (101.54) | 396.64 (113.77) | 0.316 |
Lens status (% Pseudophakic) | 62.80 | 78.70 | 0.019 |
Age (years) | 68.19 (10.12) | 69.43 (10.34) | 0.431 |
Male (%) | 64 | 31 | 0.497 |
Laterality of eye (% RE) | 46.70 | 50.80 | 0.352 |
Hypertension (% positive) | 89.10 | 75.40 | 0.014 |
Hyperlipidemia (% positive) | 89.80 | 86.90 | 0.354 |
Nephropathy (% positive) | 64.20 | 41.00 | 0.002 |
Smoker (%) | 48.90 | 52.50 | 0.379 |
BMI (%) | 34.38 (7.50) | 32.47 (8.08) | 0.108 |
Diabetes duration (years) | 22.41 (8.17) | 17.95 (9.55) | < 0.001 |
HbA1c (mg/dl) | 8.66 (1.71) | 7.68 (1.21) | 0.033 |
PRP at baseline (% positive) | 47.40 | 24.60 | 0.002 |
DR duration (years) | 7.74 (4.06) | 7.62 (3.42) | 0.848 |
Severe DR (%) | 51.80 | 36.10 | 0.028 |
Injection type | 0.599 | ||
Bevacizumab (%) | 54.70 | 55.70 | |
Ranibizumab (%) | 17.50 | 23.00 | |
Aflibercept (%) | 11.70 | 11.50 | |
Mixed (%) | 16.10 | 9.80 |